Company Overview - Norsg has a closing price of 56.0 yuan, down 2.27%, with a rolling PE ratio of 37.76 times and a total market value of 5.409 billion yuan [1] - The company operates in the medical services industry, which has an average PE ratio of 47.90 times and a median of 59.27 times, placing Norsg at the 23rd position in the industry ranking [1] Financial Performance - For Q1 2025, Norsg reported revenue of 173 million yuan, a year-on-year decrease of 2.53%, and a net profit of 26.0737 million yuan, a year-on-year increase of 13.12%, with a gross profit margin of 36.53% [1] - As of Q1 2025, there is one institutional holder of Norsg, which is a fund holding a total of 12,400 shares valued at 0.01 million yuan [1] Industry Comparison - The industry average PE ratio is 47.90 times, while the industry median is 59.27 times, indicating that Norsg's PE ratio is below both metrics [2] - Norsg's market value is 5.409 billion yuan, which is significantly lower than other companies in the industry, such as WuXi AppTec with a market value of 267.116 billion yuan [2]

通过天眼查大数据分析，诺思格(北京)医药科技股份有限公司共对外投资了7家企业，参与招投标项目 10次，知识产权方面有商标信息7条，专利信息3条，此外企业还拥有行政许可3个。 来源：金融界 金融界消息 截至2025年7月30日收盘，诺思格（301333）报收于58.72元，下跌2.3%，换手率8.42%，成 交量4.81万手，成交金额2.84亿元。 天眼查商业履历信息显示，诺思格(北京)医药科技股份有限公司，成立于2008年，位于北京市，是一家 以从事研究和试验发展为主的企业。企业注册资本9658.1256万人民币，实缴资本9658.1256万人民币。 公司法定代表人为武杰。 资金流向方面，今日主力资金净流出1348.33万元，占比成交额4.74%。其中，超大单净流出497.71万 元、占成交额1.75%，大单净流出850.62万元、占成交额2.99%，中单净流出流入343.02万元、占成交额 1.21%，小单净流入1005.32万元、占成交额3.53%。 诺思格最新一期业绩显示，截至2025一季报，公司营业总收入1.73亿元、同比减少2.53%，归属净利润 2607.37万元，同比增长13.12%，扣非净利润 ...

证券代码：301333 证券简称：诺思格 公告编号：2025-034 诺思格（北京）医药科技股份有限公司 关于公司及子公司、实际控制人诉讼进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、案件所处的诉讼阶段：再审立案审查终结。 2、上市公司所处的当事人地位：再审被申请人。 3、对上市公司损益产生的影响：对公司本期或期后利润未产生影响。 一、本次诉讼的基本情况 诺思格（北京）医药科技股份有限公司（以下简称"公司"）于2023年8月 收到北京市第四中级人民法院送达的《起诉状》《应诉通知书》（<2023>京04民 初142号）等诉讼材料，北京市第四中级人民法院受理原告钟大放起诉公司实际 控制人武杰（WU JIE）、公司及子公司圣兰格（北京）医药科技开发有限公司（以 下简称"圣兰格"）合同纠纷一案。原告钟大放诉请依据一份显示签订日期为2020 年10月21日的《协议书》复印件要求公司、子公司圣兰格、公司实际控制人武杰 （WU JIE）连带向其支付共计179,898,176元，公司、子公司圣兰格及实际控制人 武杰（WU JIE）经核实后确认各方 ...

Group 1 - The core viewpoint of the article highlights that Nossger provides clinical trial outsourcing services for innovative pharmaceutical companies [2] - The company encourages investors to refer to its regular reports and temporary announcements for detailed business information [2]

Group 1 - The core viewpoint of the news is that Norsg has experienced a stock price increase of 8.90% to 60.1 yuan, with a rolling PE ratio of 40.52, marking a new low in 108 days, and a total market capitalization of 5.805 billion yuan [1] - Norsg ranks 22nd in the medical services industry, which has an average PE ratio of 48.95 and a median of 60.06 [1] - The company has seen a net outflow of main funds amounting to 6.3644 million yuan on July 29, with a total outflow of 25.7226 million yuan over the past five days [1] Group 2 - Norsg's main business is providing comprehensive drug clinical research and development services to global pharmaceutical companies and research institutions [1] - The latest financial results for Q1 2025 show that the company achieved an operating income of 173 million yuan, a year-on-year decrease of 2.53%, and a net profit of 26.0737 million yuan, a year-on-year increase of 13.12%, with a gross profit margin of 36.53% [1] - The PE ratio of Norsg is 40.52, while the industry average is 48.95 and the industry median is 60.06 [2]

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualan Biological Engineering-B, and others [3]. Core Insights - The pharmaceutical sector has shown a 1.90% increase this week, outperforming the CSI 300 index by 0.21 percentage points. Sub-sectors such as pharmaceutical outsourcing, vaccines, and medical consumables performed well, while innovative drugs lagged behind [6][42]. - The report emphasizes the potential of the 4-1BB target in cancer treatment, particularly the PD-L1/4-1BB bispecific antibodies, which may address the limitations of PD-1/PD-L1 monotherapy [5][16][17]. Summary by Sections Industry Viewpoints and Investment Recommendations - 4-1BB is recognized as a promising target for tumor therapy, enhancing T cell activation and survival, which is crucial for effective immune responses against cancer [16]. - Investment strategies focus on the innovative drug sector, driven by increased liquidity and risk appetite, with a recommendation to pay attention to companies with strong pipelines in bispecific antibodies and ADCs [6][38]. Pharmaceutical Industry Market Performance - The pharmaceutical sector's overall P/E ratio is reported at 30.67 times, with a premium of 40.37% compared to the overall A-share market excluding financials [42]. Company Dynamics - Notable company developments include: - LIZHU Group's successful Phase III trial for a monoclonal antibody for psoriasis [43]. - Baiyang Pharmaceutical's planned share reduction by its major shareholder [43]. - Mylab's new medical device approval, enhancing market competitiveness [44]. Industry Dynamics - The report highlights the increasing focus on innovative drug development and the potential for significant market opportunities in the context of upcoming patent expirations for key small molecule drugs [38].

Core Viewpoint - The company Norse Group's stock closed at 51.94 yuan, down 1.18%, with a rolling PE ratio of 35.02 times, and a total market value of 5.016 billion yuan [1] Company Summary - Norse Group (Beijing) Pharmaceutical Technology Co., Ltd. provides comprehensive drug clinical research and development services for global pharmaceutical companies and research institutions [1] - The main products include clinical trial operation services, clinical trial site management services, data management and statistical analysis services, biological sample testing services, clinical trial consulting services, and clinical pharmacology services [1] - For Q1 2025, the company reported operating revenue of 173 million yuan, a year-on-year decrease of 2.53%, and a net profit of 26.0737 million yuan, a year-on-year increase of 13.12%, with a gross profit margin of 36.53% [1] Industry Summary - The average PE ratio for the medical services industry is 43.29 times, with a median of 47.24 times, placing Norse Group at the 24th position within the industry [2] - The industry average market value is 17.314 billion yuan, with the highest being WuXi AppTec at 226.359 billion yuan and the lowest being Huakang Clean at 2.741 billion yuan [2]

Group 1 - The A-share pharmaceutical sector experienced a strong upward trend in early trading, with significant gains in concepts such as CRO, recombinant proteins, and innovative drugs [1] - Companies like Medisi saw an increase of over 16%, while Bid Pharma rose more than 7%, with other stocks like Zhaoyan New Drug, Sunshine Nuohuo, and Nossger also following suit [1] - The National Development and Reform Commission announced that since the 14th Five-Year Plan, 402 new drugs have been added to the national medical insurance drug list [1]

Group 1 - The core point of the news is that Norsg (Beijing) Pharmaceutical Technology Co., Ltd. has applied for a patent for an automatic patient information processing system and method, which aims to enhance the accuracy of clinical drug trials and ensure patient safety [1] - The patent application was filed on June 2025, and the public announcement number is CN120260781A [1] - The method described in the patent involves several steps, including gathering historical case information, selecting suitable trial patients, assessing their safety levels, and categorizing trial data [1] Group 2 - Norsg (Beijing) Pharmaceutical Technology Co., Ltd. was established in 2008 and is based in Beijing, focusing on research and experimental development [2] - The company has a registered capital of 96.581256 million RMB and has made investments in 7 enterprises [2] - Norsg has participated in 10 bidding projects and holds 7 trademark registrations and 2 patent registrations, along with 3 administrative licenses [2]

Group 1 - The core viewpoint of the news is the release of the "Several Measures to Support the High-Quality Development of Innovative Drugs," which aims to enhance support for innovative drug research and development through various initiatives [1][3]. - The measures include 16 specific actions across five areas, such as increasing R&D efforts, supporting innovative drugs' inclusion in basic medical insurance and commercial health insurance directories, and improving clinical application and payment capabilities [4][5]. - The approval of 41 first-class innovative drugs by the National Medical Products Administration this year indicates a significant rise in domestic pharmaceutical companies' capabilities, with over 85% of these drugs being developed by Chinese firms [2][3]. Group 2 - The "Several Measures" are a refinement of the "Full Chain Support Plan for Innovative Drug Development," which was established to address current challenges in the innovative drug sector [3][4]. - The introduction of a dynamic adjustment mechanism for the medical insurance directory allows most innovative drugs to be included within two years of market launch, while the new commercial health insurance directory provides alternative payment channels for innovative drugs [5][6]. - The measures aim to address the entire lifecycle of innovative drugs, tackling issues related to R&D, payment, and clinical access, thereby attracting more capital and talent to the innovative drug sector [6].